Cooley LLP announced today that it advised Otsuka in its $825 million collaboration agreement with Lundbeck to further the development and commercialization of a developmental drug, Lu AE58054, for the treatment of Alzheimer’s disease.
Under the terms of the agreement, Lundbeck will receive an initial payment of $150 million and both companies will share the sales, development, and commercialization costs. In exchange, Lundbeck will grant Otsuka co-development and co-commercialization rights to Lu AE58054 in the US, Canada, East Asia, including Japan, and in major European and Nordic countries.
Otsuka is a global healthcare company that researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health. Lundbeck is a global pharmaceutical company committed to improving the quality of life of people living with brain diseases.
The Cooley team that advised Otsuka was led by Seattle-based of counsel, Alison Freeman-Gleason and Palo Alto-based partner Lila Hope and included Washington, DC-based partner Thomas Blinka.
Related Posts:
- Cooley Represents Molecular Partners in Broad Collaboration with Allergan
- Ambit Biosciences to be Acquired by Daiichi Sankyo for $410 Million
- Cooley Represents Trius Therapeutics in Acquisition by Cubist Pharmaceuticals
- Cooley Advises Portola Pharmaceuticals on its $140 Million IPO
- Cooley Advises Kite Pharma on $146 Million Initial Public Offering
